Literature DB >> 33766464

Systemic dissemination of tumor cells during transurethral resection in patients with bladder tumor and its clinical relevance: A follow up study.

Rishi Nayyar1, Sumit Saini2, Alpana Sharma3, Santosh Kurra3, Prem Nath Dogra1.   

Abstract

OBJECTIVE: Tumor cells are shed during transurethral resection of bladder tumor (TURBT) and form the basis for use of single dose immediate chemotherapy instillation to reduce recurrences. Systemic dissemination of these cells along with the irrigation fluid is also possible but not consistently proven. In this study, we evaluated such dissemination of tumor cells into the circulation during TURBT and its clinical impact.
METHODS: Patients with primary presentation of bladder tumor who underwent TURBT were included. Peripheral venous blood samples before and after TURBT were analyzed for circulating tumor cells (CTCs) using flow-cytometry. A CD45 negative cell with positive expression of cytokeratin 18, 19, and EpCam was defined as CTC. The CTC counts, pre and post TURBT, were compared and correlated with final histopathology. The patients were also followed up for any local and/or systemic recurrences.
RESULTS: Nine (16.98%) out of 53 patients developed a measurable rise in CTCs after TURBT. All of these patients had high grade and muscle invasive disease. Overall, a measurable rise in CTCs was seen in 9 out of 17 (52.94%) patients with muscle invasive disease. There was no difference in the clinico-pathological stage or the status of cystectomy and/or chemotherapy between those who did or did not show a rise in CTCs. On follow up, 7 patients with muscle invasive disease developed local and/or systemic recurrences and the rise in CTCs was not found to be associated with adverse oncological outcomes.
CONCLUSIONS: This study confirms the hypothesis of inadvertent dissemination of tumor cells into the circulation during TURBT, especially in patients with high grade and muscle invasive disease. The long-term oncological impact of such dissemination remains to be confirmed.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Circulating tumor Cells; Flow cytometry; Hematogenous dissemination; Muscle invasive bladder carcinoma; Transurethral resection of bladder tumor

Mesh:

Substances:

Year:  2021        PMID: 33766464     DOI: 10.1016/j.urolonc.2021.02.019

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  3 in total

1.  Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature.

Authors:  Tianyuan Xu; Wenyu Gu; Xianjin Wang; Leilei Xia; Yanyan He; Fan Dong; Bin Yang; Xudong Yao
Journal:  World J Surg Oncol       Date:  2022-07-06       Impact factor: 3.253

2.  Case of the month from the University of Sheffield, UK: Expediting definitive treatment in patients with invasive bladder cancer: an MRI-guided pathway.

Authors:  Samantha Conroy; Rachel Hubbard; Aidan P Noon; Syed A Hussain; Jon Griffin; Steven Kennish; James W F Catto
Journal:  BJU Int       Date:  2022-06       Impact factor: 5.969

Review 3.  Diagnostic Potential of Circulating Tumor Cells, Urinary MicroRNA, and Urinary Cell-Free DNA for Bladder Cancer: A Review.

Authors:  Dai Koguchi; Kazumasa Matsumoto; Izuru Shiba; Takahiro Harano; Satoshi Okuda; Kohei Mori; Shuhei Hirano; Kazuki Kitajima; Masaomi Ikeda; Masatsugu Iwamura
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.